Interestingly, the neoplasm extended throughout the bladder wall with areas of necrosis of some of the neoplasm. At the same time a separate and well differentiated adenocarcinoma of the prostate was identified.
There appears to be no statistically significant series reported with regard to this disease or its management excepting surgical removal. I would like to think that the Mitomycin-C was responsible for the necrosis identified in the surgical specimen, and would urge its consideration as adjunctive therapy for this disease which is so difficult both to immediately recognize and satisfactorily treat. The patient will be followed by appropriate tumour markers and computerized axial tomography. Sincerely S DWANE THOMAS 4 May 1983
Treatment of cramp From Dr Alan A Morgan Ilford, Essex
Sir, I was interested to read the review on cramp by Dr Joekes (July 1982 Journal. p 546) and in particular his view that there was no satisfactory treatment for cramps in pregnancy. Dr Patterson (December 1982, p 988), commenting on this, mentions the success she has had for cramps in her own two pregnancies with weekly intravenous injections of calcium. I would like to mention a simple and safe treatment.
Kleine (\ 954) described 80 cases of cramps in pregnancy, all successfully treated with either oral or intravenous riboflavine. Thoyer-Rozat et al. (1960) had only three refractory cases in his series using riboflavine orally. Cantaluppi (1962) also mentions its value in pregnancy cramps. Perrault et al. (\946) extended its use with success in muscle cramps associated with a variety of disorders (diabetes, circulatory disturbances, infections and diverse intoxications).
The exact mechanism of riboflavine in alleviating cramps is still undetermined, although its effect on neuromuscular irritability has been studied by Haralambie (1976) and may prove relevant.
Dr Rivlin (April Journal, p 326) questions the wisdom of prescribing drugs for cramps in pregnancy; however, riboflavine does not produce toxic effects even in large dosage and there have been no published reports of any teratogenic effects. On the contrary, deficiency of this vitamin has been reported as resulting in congenital malformations (Rivlin 1970) .
It is of interest that Martindale (19IQ) states that there is little evidence that riboflavine has any therapeutic value except in the treatment of ariboflavinosis. In fact, there is no longer any proprietary brand of riboflavine produced in Great Britain, Roche having withdrawn its own product (Bcflavit) some years ago.
Having, however, personally successfully treated many cases of cramps in pregnancy with riboflavine in a dosage of 18 mg daily, I can certainly corroborate the work of previous authors. The patient should of course be warned that the urine may be coloured red or orange. Yours sincerely ALAN This new Association, which has been supported with a launching grant from the Commonwealth Foundation, has as its principal aims 'the prevention and amelioration of mental handicap and associated developmental difficulties in developing countries'.
The Association is, as yet, only a few months old and is currently concerned to make its existence known to as many as possible who are concerned with the field of mental handicap, particularly as this relates to the developing countries, either hecause they are directly involved with work within such countries, or interested in supporting such work. The membership will ultimately be that of professional and non-professional workers. It is hoped that what will be created is something of a network of such workers throughout the Commonwealth, and that from time to time practically-orientated regional training workshops
